/주식/RCUS
RCUS

RCUS

USD

Arcus Biosciences Inc. Common Stock

$19.830+0.130 (0.660%)

실시간 가격

Healthcare
생명공학
미국

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$19.700

고가

$20.500

저가

$19.691

거래량

0.41M

기업 기본 정보

시가총액

2.4B

산업

생명공학

국가

United States

거래 통계

평균 거래량

1.18M

거래소

NYQ

통화

USD

52주 범위

저가 $6.5현재가 $19.830고가 $22.11

관련 뉴스

BusinessWire

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune

더 보기
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Analyst Upgrades

Goldman Sachs Maintains Neutral on Arcus Biosciences, Raises Price Target to $16

Goldman Sachs analyst Salveen Richter maintains Arcus Biosciences with a Neutral and raises the price target from $14 to $16.

더 보기
Goldman Sachs Maintains Neutral on Arcus Biosciences, Raises Price Target to $16
Analyst Upgrades

Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $56

Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences with a Buy and raises the price target from $54 to $56.

더 보기
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $56
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $28

HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences with a Buy and raises the price target from $24 to $28.

더 보기
HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $28
BusinessWire

Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update

Casdatifan, a potential best-in-class HIF-2a inhibitor, demonstrated 12.2 months median progression-free survival (mPFS) and 18-month landmark PFS of 43% in a pooled analysis of 121 patients with late-line kidney

더 보기
Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update
Analyst Upgrades

Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $54

Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences with a Buy and raises the price target from $47 to $54.

BusinessWire

Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study

First overall survival (OS) results from Arm A1 of the Phase 2 EDGE-Gastric study will be presented on October 18 at the European Society for Medical Oncology (ESMO) 2025 Congress These data support the ongoing